Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.58 |
| ▸ | AXL | P30530 | 1/20 | 0.54 |
| ▸ | GAK | O14976 | 2/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.44 |
| ▸ | COQ8A | Q8NI60 | 2/20 | 0.44 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.44 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.44 |
| ▸ | AURKA | O14965 | 2/20 | 0.42 |
| ▸ | KIT | P10721 | 2/20 | 0.42 |
| ▸ | IRAK4 | Q9NWZ3 | 2/20 | 0.42 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4036286 | 0.86 | FLT3 (0.64) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4038658 | 0.85 | FLT3 (0.61) | FLT3AXLPTK2AURKAKIT | |
| SCHEMBL4038352 | 0.84 | FLT3 (0.80) | FLT3AXLGAKRIPK2COQ8A | |
| SCHEMBL4039143 | 0.83 | FLT3 (0.80) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4038836 | 0.82 | FLT3 (0.81) | FLT3AXLGAKRIPK2COQ8A | |
| SCHEMBL4040469 | 0.76 | FLT3 (0.73) | FLT3AXLPTK2AURKAKIT | |
| SCHEMBL2086558 | 0.76 | FLT3 (0.80) | FLT3AXLPTK2AURKAKIT | |
| SCHEMBL4042878 | 0.75 | FLT3 (0.65) | FLT3AXLGAKRIPK2COQ8A | |
| SCHEMBL2085464 | 0.74 | FLT3 (0.54) | FLT3AXLAURKAKITIRAK4 | |
| SCHEMBL4036749 | 0.74 | FLT3 (1.00) | FLT3AXLAURKAKITIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| US-7902239-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-08 | — | — | US | disclosed |
| EP-2051708-A2 | EPITOPE REDUCTION THERAPY | ISIS Innovation Limited (GB) | 2009-04-29 | — | — | EP | disclosed |
| EP-1562589-B1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008012555-A2 | EPITOPE REDUCTION THERAPY | ISIS INNOVATION LIMITED (GB) | 2008-01-31 | — | — | WO | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279469-B2 | Diaminotriazoles useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-10-09 | — | — | US | disclosed |
| CN-1738615-A | Diaminotriazoles as inhibitors of protein kinases | VERTEX PHARMA (US) | 2006-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080014189-A1 | DIAMINOTRIAZOLES USEFUL AS INHIBITORS OF PROTEIN KINASES | MAP3K20, MAP3K1, MAP3K5 | FLT3 220/4885AXL 762/4885GAK 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.